SPOTLIGHT -
Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid Malignancies
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Shubham Pant, MD, on the Future of Treatment of Pancreatic Cancer With Targeted Therapies
Shubham Pant, MD, highlights the importance of tailoring treatment in patients with pancreatic cancer by exploring biomarkers.
Shubham Pant, MD, Highlights Outcomes With Erdafitinib in Gastrointestinal Cancers
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.
Barriers to Pancreatic Cancer Clinical Trials Enrollment
